The MHRA is urging pharmacies to return certain batches of the migraine treatment Imigran Injection/Subject to their supplier in response to concerns that some of the syringes could be contaminated.

The medicines watchdog issued the warning yesterday (October 29) after GlaxoSmithKline UK recalled five batches of the injection because a manufacturing fault had caused some of the needles to protrude from the protective shields.

The risk to the public finding an affected syringe was extremely low, the MHRA stressed	More on the MHRA Recall of 10 Wockhardt UK medicines Drug watchdogs give combined pill the thumbs up Printing error prompts MHRA withdrawal of Natzon batches MORE NEWS
	The number of needles affected was thought to be very small and therefore the risk to the public finding an affected syringe was extremely low, the MHRA stressed.

"There is, however, a slight risk of infection from an unprotected needle and we would ask people to take extra care when using these syringes," said Adam Burgess, MHRA manager of the Defective Medicines Recall Centre.

The affected batch numbers are:

Imigran Inj/ Subject Treatment –C640404, C638748, C636954

Imigran Inj / Subject Treatment Refill –C639899, C638737